Findings from a new study on the efficacy of the advanced radioactive tracer Fluciclovine in radiation treatment have revealed that it significantly improves the chance of patient survival without the reoccurrence of cancer. This conclusion came after 75.5 percent of patients who had recurrent prostate cancer and were imaged with the radiotracer survived for three
